371 related articles for article (PubMed ID: 35628931)
1. Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.
Robak E; Robak T
J Clin Med; 2022 May; 11(10):. PubMed ID: 35628931
[TBL] [Abstract][Full Text] [Related]
2. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
Robak T; Witkowska M; Smolewski P
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159041
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
5. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
[TBL] [Abstract][Full Text] [Related]
6. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
7. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
8. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Palma M; Mulder TA; Österborg A
Front Immunol; 2021; 12():686768. PubMed ID: 34276674
[TBL] [Abstract][Full Text] [Related]
9. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
St-Pierre F; Ma S
Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
[TBL] [Abstract][Full Text] [Related]
10. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
11. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
[TBL] [Abstract][Full Text] [Related]
13. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
14. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
von Hundelshausen P; Siess W
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806595
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
De Bondt M; Renders J; Struyf S; Hellings N
Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Zhao ZX; Yang TY; Wang YH; Zhang L; Li J; Su YW
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38831641
[TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
18. The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.
Dispenza MC
Curr Treat Options Allergy; 2021; 8(3):261-273. PubMed ID: 33880321
[TBL] [Abstract][Full Text] [Related]
19. The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.
Tambaro FP; De Novellis D; Wierda WG
J Exp Pharmacol; 2021; 13():923-935. PubMed ID: 34744463
[TBL] [Abstract][Full Text] [Related]
20. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]